Short answer
Azenta, Inc. (AZTA) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal fourth-quarter and full-year 2026 results announced for period ended September 30, 2026.
Azenta, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal fourth-quarter and full-year 2026 results announced for period ended September 30, 2026
- Detailed financial results and management commentary contained in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- FY26 revenue $622M, up 5% reported and 2% organically, but adjusted EBITDA fell 12% to $58.3M
- FY26 GAAP operating loss $174.7M, including $149.1M goodwill and intangible impairment
- Sample Management Solutions grew 6% to $344M, while Multiomics grew 3% to $277M
- FY27 revenue guidance $648M-$660M, with organic growth of 3%-5% and adjusted EBITDA margin expansion of 200-250 basis points
- Elegen and SynPlexity investments could require $32M-$71M and add up to $10M contingent consideration, increasing execution and integration risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Azenta, Inc. 8-K filings
Get the next AZTA 8-K as it lands
Follow AZTA for push alerts, or ask the research agent what this filing means.